Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

BACKGROUND

Checkpoint inhibitor (CPI) therapy revolutionized treatment for advanced non-small-cell lung cancer (NSCLC); however, most patients progress due to primary or acquired resistance. Sitravatinib is a receptor tyrosine kinase inhibitor that can shift the immunosuppressive tumor microenvironment toward an immunostimulatory state. Combining sitravatinib with nivolumab (sitra + nivo) may potentially overcome initial CPI resistance.

PATIENTS AND METHODS

In the phase III SAPPHIRE study, patients with advanced non-oncogenic driven, nonsquamous NSCLC who initially benefited from (≥4 months on CPI without progression) and subsequently experienced disease progression on or after CPI combined with or following platinum-based chemotherapy were randomized 1 : 1 to sitra (100 mg once daily administered orally) + nivo (240 mg every 2 weeks or 480 mg every 4 weeks administered intravenously) or docetaxel (75 mg/m2 every 3 weeks administered intravenously). The primary endpoint was overall survival (OS). The secondary endpoints included progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR), duration of response (DOR; all assessed by blinded independent central review), and safety.

RESULTS

A total of 577 patients included randomized: sitra + nivo, n = 284; docetaxel, n = 293 (median follow-up, 17.1 months). Sitra + nivo did not significantly improve OS versus docetaxel [median, 12.2 versus 10.6 months; hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.70-1.05; P = 0.144]. The median PFS was 4.4 versus 5.4 months, respectively (HR 1.08, 95% CI 0.89-1.32; P = 0.452). The ORR was 15.6% for sitra + nivo and 17.2% for docetaxel (P = 0.597); CBR was 75.5% and 64.5%, respectively (P = 0.004); median DOR was 7.4 versus 7.1 months, respectively (P = 0.924). Grade ≥3 treatment-related adverse events were observed in 53.0% versus 66.7% of patients receiving sitra + nivo versus docetaxel, respectively.

CONCLUSIONS

Although median OS was numerically longer with sitra + nivo, the primary endpoint was not met in patients with previously treated advanced nonsquamous NSCLC. The safety profiles demonstrated were consistent with previous reports.

Wounding the stroma: Docetaxel's role in dormant breast cancer escape

The mechanistic underpinnings of breast cancer recurrence following periods of dormancy are largely undetermined. A new study in PLOS Biology reveals that docetaxel-induced injury of tumour stromal cells stimulates the release of cytokines that support dormancy escape of breast cancer cells.

Dendrobium officinalis inhibited tumor growth in non-small cell lung cancer

Background

Lung cancer is the most common and lethal tumor in the world, and the number of patients who die from lung cancer is growing steadily. Because of conventional chemotherapy drugs’ poor tumor selectivity, side effects are significant. Conducting relevant studies and developing highly efficient and low toxicity anti-cancer drugs are urgently needed. Dendrobium officinale, which belongs to Orchidaceae aerophyte, has the characteristic of slow growth and lower natural propagation rate. In China, Dendrobium officinale has a very high value and is often referred to as the “gold of herbs”. According to reports in the literature, the active ingredients of Dendrobium officinale have anticancer activity and inhibit neovascularization’s potential. This study aimed to investigate the inhibitory effect of Dendrobium officinale in A549 lung cancer cells and its potential involvement in slowing tumor growth.

Methods

We cultured A549 cells and established a cancer xenograft model in nude mice. Infused stomach with Dendrobium officinale was applied to the nude mouse model. Tumor volume and body weight were recorded.

Results

The results show that, compared with the negative control group, the gross tumor volume (GTV) of treatment groups decreased (all P<0.05), while the effect of the high concentration of the Dendrobium officinale was more significant than that found in the medium and low group. We believe that Dendrobium officinale exhibits a promising antitumor effect in the nude mouse tumor model. The best treatment concentrations for the nude mouse tumor model were achieved when treatment with the drug began about 7–15 days, and was more significant in high concentrations.

Conclusions

Dendrobium officinale has potent effects of inhibiting tumor on the nude mouse tumor model.